期刊文献+

NSE在骨髓瘤骨病中的表达 被引量:7

The Expression of Neuron Specific Enolase in Multiple Myeloma Patients
原文传递
导出
摘要 目的多发性骨髓瘤(MM)是来源于B淋巴细胞的恶性肿瘤,以终末分化的浆细胞的克隆性增生为显著特征。骨质破坏是其突出的临床特点之一,与疾病的预后直接相关。多种细胞因子参与了骨质破坏的过程。加强对MM骨病机制的研究将为临床靶向治疗和改善患者生存质量提供更好的依据。本研究旨在探讨神经元特异性烯醇化酶(NSE)在骨髓瘤骨病中的作用。方法采用ELISA和实时荧光定量RT-PCR方法,对MM患者血浆和骨髓中以及骨髓瘤细胞株U266中NSE水平进行定量分析,初步分析其在骨髓微环境中的表达情况,了解其与MM骨病的关系。结果U266和67%的患者中NSE水平明显高于对照组(P<0.01),且随着临床分期和骨质破坏程度的增加,NSE表达总体呈上升趋势。结论 U266和大部分骨髓瘤骨病患者中NSE表达水平增高,且与MM骨病程度和疾病分期相关,提示NSE可能在骨髓瘤骨病中起重要作用。 Objective Multiple myeloma(MM) was characterized by cloning proliferation of terminally differentiated plasma ceils. The bone destruction,which serves as a predominant clinical feature of MM patients, was closely related to prognosis. A se- ries of cytokines had been proved to work in myeloma bone disease. To explore the mechanism of MBD would be helpful for effec- tive targeted therapies and improving life quality of MM patients. In order to explore the role of neuron specific enolase(NSE) in myeloma bone disease(MBD). Methods ELISA and real-time PCR was used to quantitate the NSE in multiple myeloma and MM cell line( U266 ). Based on the data, the levels in bone marrow microenvironment and the associations between myeloma bone disease and myeloma cells were analyzed. Results The results showed that U266 and about 67% patients with multiple myeloma had increased levels and copies. A significantly larger proportion of MM patients had increased levels of NSE compared to the con- trol ( P 〈 0.01 ), NSE levels increased progressively according to the bone damage degree and clinical stages. Conclusion U266 and most of patients with MBD had increased levels of NSE. The up regulation of NSE may contribute to myeloma bone disease and stages, indicating that it was probably another critical cytokine which triggers bone damage.
出处 《中华全科医学》 2012年第3期337-338,F0003,共3页 Chinese Journal of General Practice
基金 2007年云南省科技厅教育厅联合专项(2007C0037R)
关键词 多发性骨髓瘤 神经元特异性烯醇化酶 骨质破坏 Multiple myeloma Neuron specific enolase(NSE) Bone lesions
  • 相关文献

参考文献12

  • 1Roodman GD. Pathogenesis of myeloma bone disease [ J ]. Leukemia, 2009,23 ( 3 ) :435-441.
  • 2Barille-Nion S, Bataille R. New insights in myeloma-induced osteolysis [ J ]. Leuk Lymphoma, 2003,44 (9) : 1463-1467.
  • 3Breitkreutz I, Raab MS, Vallet S, et at. Lenalidomide inhibits osteoelas- togenesis, survival factors and bone-remodeling markers in multiple myeloma[ J]. Leukemia,2008,22(10) :1925-1932.
  • 4Sharma RA, Wotherspoon AC, Cook G, et al. Neuron specific enolase expression in multiple myeloma [ J ]. Lancet Oncol,2006,7 (11 ) :960.
  • 5Alexandrakis MG, Passam FH, Sfiridaki A, et al. Elevated serum con- centration of hepatocyte growth factor in patients with multiple myelo- ma: correlation with markers of disease acticvity[ J]. Am J Hematol, 2003,72(4) :229-233.
  • 6Silvestris F, Lombardi L, De Matteo M, et al. Myeloma bone disease: Pathogenetic mechanisms and clinical assessment [ J ]. Leuk Res, 2007,31 (2) : 129-138.
  • 7Hashimoto T,Abe M, Oshima T, et al. Ability of myeloma ceils to se- crete macrophage inflammatory protein(MIP)-1 alpha and MIP-1 beta correlates with lyric bone lesions in patients with multiple myeloma [J]. Br J Haematol,2004,125( 1 ) :38-41.
  • 8梁成,孔凡元.神经元特异性烯醇化酶检测与临床研究[J].宁夏医学院学报,2004,26(2):129-131. 被引量:5
  • 9Sorhaug S, Steinshamn S, Haaverstad R, et al. Expression of neureen- docrine markers in non-small cell lung cancer[ J]. APMIS,2007,115 (2) :152-163.
  • 10Cata JP, Abdelmalak B, Farag E. Neurological biomarkers in the peri- operative period[ J]. Br J Anaesth,2011,107 (6) :844-858.

二级参考文献22

  • 1Beliaeva IA, Antonova OM, Anin AN, et al. Resistance of the hemato- encephalic carrier in tick- borne neural infection (Lyme disease and tick borne encephalitis) [J].Zh Nevropatol Psikhiatr Irn S S korsakova, 1995, 95(6):25-29
  • 2Mercer DW, Virji MA, Barry GE, et al. New Solid - phase Enzyme Immunoassay of Neuron- Specific Enolase in Serum: Effect of Storage Temperature, Lipemia, Icterus, and Hemolysis, DW [J] .J Clin Chem, 1990, 36(8): 1519-1122
  • 3Marargos PJ, Schmechel D, Parma AM, et al. Measurement of neuron - specific enolase(NSE) and non - neuronal enolase (NNE) isoenzymes of enolase in rat, monkey, and human nervous tissue[J].J Neurochem, 1979, 33(1): 319-329
  • 4Hermann M Curio N, Jost S, et al . Release of biochemical markers of damage to neuronal and glial brain - tissue is associated with short and long term neuropsychological outcome afeter traumatic brain injury[J]. J Neurol Neurosury Psychiatry , 2001 70,(1
  • 5Thornberg E, Thiringer K, Haberg H, et al. Neuron specific enolase in asphyxiated newborns associated with encephalopathy and cerebral function monitor trace[J]. Arch Dis Child Fetal Neonatal Ed, 1995, 72(1) :39- 42
  • 6Inoue S, Takahashi H, Kaneko K . The fluctuations of neuron- specific enolasec (NSE), levels of cerebrospinal fluid during bacterial meningitis, the relationship between the fluctuations of NSE levels and neurological complications or outcome[J]. Acte Pae
  • 7Studabl M,Rosengren L, Guneher G, et al. Difference in pathogenesis between herpes simplex virus type I encephalitis and tick - borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction[J]. J Neurol, 2000,24
  • 8Vermuyten K, et al. Detection of neuron specific enolase concentrations in cerebrospinal fluid from patients with neurological disorders by means of a sensitive enzyme immunoassay [J]. Clin Claim Acta, 1990, 187:69-78
  • 9Fridriksson T, Kini N, Walsh- Kelly C, et al. Serum neuron- specific enolase as a predictor of intracranial lesions in children with headtrauma: a pilot study[J]. Acad Emerg Med, 2000, 7(7) :816 - 882
  • 10DeGiorgio CM, Correale JD,Gott PS,et al. Serum neuron - specific enolase in human status epilepticus[J]. Neurology, 1995, 451: 134

共引文献4

同被引文献84

  • 1贺勇,尤志珺,周少华,邓晓玲.短暂性脑缺血发作患者血清S-100和神经元特异性烯醇化酶的测定及临床意义[J].实用医学杂志,2005,21(1):37-38. 被引量:7
  • 2舒志荣,蔡文仙,孙立荣.急性淋巴细胞白血病患儿化疗时脑脊液神经元特异性烯醇化酶的变化及意义[J].中国实用儿科杂志,2005,20(5):289-290. 被引量:4
  • 3樊慧杰,耿其荣,徐海鹏,陈晓勤,吕跃.血清神经元特异性烯醇化酶水平在非霍奇金淋巴瘤中的临床意义[J].中国肿瘤,2006,15(1):50-53. 被引量:6
  • 4Slosberg P S. The neuroprotective effect of dexmedetomidine in the hippocampus of rabbits after subarachnoid hemorrhage[J]. Surg Neruol, 2009,72 (6) : 648-650.
  • 5Kuhmonen J, Pokorny J, Miettinen R, et al. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia[-J]. Anesthesiology, 1997,87 (2) : 371- 377.
  • 6Tanskanen P E, Kytta J V, Randell T R, et a! Dexmedetomidine as an anesthetic adjuvant in patient undergoing intracranial tumor surgery a double-blind randomized and placebo controlled study[J]. Br J Anesth 2006,97(5) =658 665.
  • 7Huang R, Chen Y, Yu A C, et al. Dexmedetomidine-indueed stimulation of glutamine oxidation in astrocytes: a possible mechanism for its neuroprotective activity[-J]. J Cereb Blood Flow Metab,2000,20(6) :895-898.
  • 8Dahmani S, Paris A, Jannier V, et aZ. Dexmedetomidine increases hippocampal phosphorylated extracellular signal regulated protein kinase 1 and 2 content by an alpha2- adrenoceptor-independent mechanism evidence for the involvement of imidazoline 1I receptors[J]. Anesthesiology, 2008,108(3) : 457-466.
  • 9Merie E, Gunduz A, Turedi S, et al. The prognostic value of neuron- specific enolase in head trauma patients[J]. J Emerg Med, 2010, 38: 297-301.
  • 10Osterlundh G, Bjure J, Lannering B, et al. Regional cerebral blood flow and neuron-specific enolase in cerebrospinal fluid in children with acute lymphoblastic leukemia during induction treatment [J]. J Pediatr Hematol Oncol, 1999, 21: 378-383.

引证文献7

二级引证文献126

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部